Abstract
Ladostigil, propargyl-(3R) aminoindan-5yl)-etyl-metyl karbamát] as prepared in order to combine the neuroprotective effects of rasagiline, a selective inhibitor of monoamine oxidase-B with the cholinesterase inhibitory activity of rivastigmine as a potential treatment for Alzheimer‘s disease. Further studies of pharmacological profile revealed, that ladostigil possesses neuroprotective and antioxidant properties, therefore can be described as multitargeted drug.
This drug was developed for the treatment of comorbidity of dementia with Parkinsonism, since approximately 40% of dementia patients suffer from both diseases. The Phase 2 of clinical trial to evaluate the safety and efficacy of patients diagnosed with mild cognitive impairment (MCI) has been commencement.